The shadow of Brexit on speed of accessNo-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share XThe shadow of Brexit on speed of accesshttps://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
The new CDF – Navigating Cancer Drug Access in EnglandOn July 29th 2016, the new process in England for cancer drugs seeking license went live – changing Share XThe new CDF – Navigating Cancer Drug Access in Englandhttps://pharmaphorum.com/partner-content-oncology/new-cdf-navigating-cancer-drug-access-england/
Available on-demand: The Price is Right? – Delivering UK access for niche patient populations With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what Share XAvailable on-demand: The Price is Right? – Delivering UK access for niche patient populationshttps://pharmaphorum.com/debates-insight-market-access/live-webinar-the-price-is-right-uk-niche-market-access/
